Dr. Surya P. Bhatt, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 66
Licensed in Alabama since 2012, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AL license 31641 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 151
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 63 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Bethlehem, PA | 26 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Bethlehem, PA | 26 |
| Azithromycin Other prescribers in Bethlehem, PA | 20 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Bethlehem, PA | 19 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Bethlehem, PA | 11 |
| Alprazolam Other prescribers in Bethlehem, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 117 payments worth $211,501 in total to this clinician.
| Genzyme Corporation | $78,227 |
|---|---|
| Sanofi US Services Inc. | $30,761 |
| AstraZeneca Pharmaceuticals LP | $22,333 |
| Regeneron Pharmaceuticals, Inc. | $19,322 |
| F. Hoffmann-la Roche AG | $18,906 |
| Genentech USA, Inc. | $8,899 |
| Sanofi-aventis U.S. LLC | $7,014 |
| GlaxoSmithKline, LLC. | $5,237 |
| Consulting Fee | $137,444 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $49,020 |
| Travel and Lodging | $21,103 |
| Food and Beverage | $3,933 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Mar 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $29,926 |
| Genzyme Corporation Jun 6, 2025 | Consulting Fee | $16,841 |
| Genzyme Corporation Nov 21, 2025 | Consulting Fee | $16,012 |
| Genzyme Corporation Mar 1, 2025 | Consulting Fee | $13,251 |
| Genzyme Corporation Jul 14, 2025 | Consulting Fee DUPIXENT · Immunology | $12,700 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Travel and Lodging travel to Zurich, Switzerland | $11,019 |
| Genentech USA, Inc. Jun 7, 2025 | Consulting Fee | $8,220 |
| Genzyme Corporation May 17, 2025 | Consulting Fee DUPIXENT · Immunology | $5,734 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Consulting Fee | $5,610 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,010 |
All 69 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,175 |
| Regeneron Healthcare Solutions, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Regeneron Healthcare Solutions, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Genzyme Corporation Dec 17, 2025 | Travel and Lodging travel to Philadelphia, PA | $66.90 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity | $269 |
| Genzyme Corporation Nov 21, 2025 | Consulting Fee | $16,012 |
| AstraZeneca Pharmaceuticals LP Nov 21, 2025 | Travel and Lodging travel to Amsterdam, Netherlands Company’s descriptionResearch Related Service | $71.61 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Travel and Lodging FASENRA · Respiratory · travel to Chicago, IL Company’s descriptionConsulting Expenses | $42.44 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Travel and Lodging FASENRA · Respiratory · travel to Chicago, IL Company’s descriptionConsulting Expenses | $32.93 |
| Genzyme Corporation Nov 11, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $638 |
| AstraZeneca Pharmaceuticals LP Nov 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $3,491 |
| GlaxoSmithKline, LLC. Nov 4, 2025 | Consulting Fee | $3,250 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Consulting Fee FASENRA · Respiratory | $1,611 |
| Aero US Inc Oct 18, 2025 | Consulting Fee AEROGEN SOLO NEBULIZER SYSTEM; AEROGEN USB CONTROLLER SYSTEM; AEROGEN SOLO NEBULIZER SYSTEM · RESPIRATORY | $2,972 |
| AstraZeneca Pharmaceuticals LP Oct 18, 2025 | Travel and Lodging FASENRA · Respiratory · travel to Chicago, IL · in-kind Company’s descriptionConsulting Expenses | $510 |
| AstraZeneca Pharmaceuticals LP Oct 18, 2025 | Travel and Lodging FASENRA · Respiratory · travel to Chicago, IL · in-kind Company’s descriptionConsulting Expenses | $510 |
| AstraZeneca Pharmaceuticals LP Oct 8, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $3,222 |
| Sanofi US Services Inc. Oct 3, 2025 | Consulting Fee | $835 |
| Sanofi Pasteur Inc. Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,132 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Consulting Fee BREZTRI · Respiratory | $2,148 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Consulting Fee FASENRA · Respiratory | $2,148 |
| AstraZeneca Pharmaceuticals LP Sep 19, 2025 | Consulting Fee | $2,148 |
| AstraZeneca Pharmaceuticals LP Sep 12, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to Dallas, TX · in-kind Company’s descriptionSpeaker Expenses | $393 |
| AstraZeneca Pharmaceuticals LP Sep 12, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to Dallas, TX · in-kind Company’s descriptionSpeaker Expenses | $284 |
| AstraZeneca Pharmaceuticals LP Sep 12, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to Dallas, TX · in-kind Company’s descriptionSpeaker Expenses | $57.61 |
| AstraZeneca Pharmaceuticals LP Sep 3, 2025 | Consulting Fee FASENRA · Respiratory | $537 |
| Eli Lilly and Company Aug 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $800 |
| Roche Products Limited Aug 1, 2025 | Consulting Fee | $3,083 |
| Genzyme Corporation Jul 14, 2025 | Consulting Fee DUPIXENT · Immunology | $12,700 |
| Genzyme Corporation Jul 14, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Boston, MA · in-kind | $842 |
| Genzyme Corporation Jul 14, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Boston, MA · in-kind | $814 |
| Genzyme Corporation Jul 14, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Boston, MA · in-kind | $348 |
| F. Hoffmann-la Roche AG Jul 7, 2025 | Consulting Fee | $1,541 |
| GlaxoSmithKline, LLC. Jun 25, 2025 | Consulting Fee | $1,300 |
| Genentech USA, Inc. Jun 7, 2025 | Consulting Fee | $8,220 |
| Genentech USA, Inc. Jun 7, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $272 |
| Genentech USA, Inc. Jun 7, 2025 | Travel and Lodging travel to Rosemont, IL | $34.79 |
| Genzyme Corporation Jun 6, 2025 | Consulting Fee | $16,841 |
| Genzyme Corporation Jun 6, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $206 |
| GlaxoSmithKline, LLC. Jun 3, 2025 | Consulting Fee | $650 |
| Chiesi USA, Inc. May 25, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $393 |
| Chiesi USA, Inc. May 24, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $1,896 |
| Chiesi USA, Inc. May 24, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $160 |
| Genzyme Corporation May 17, 2025 | Consulting Fee DUPIXENT · Immunology | $5,734 |
| Genzyme Corporation Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,099 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,010 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,175 |
| Genzyme Corporation Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,099 |
| AstraZeneca Pharmaceuticals LP Mar 24, 2025 | Travel and Lodging travel to London, Great Britain (UK) Company’s descriptionResearch Related Service | $29.96 |
| Polarean, Inc. Mar 21, 2025 | Consulting Fee XENOVIEW · Respiratory | $2,500 |
| Sanofi US Services Inc. Mar 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $29,926 |
| Genzyme Corporation Mar 1, 2025 | Consulting Fee | $13,251 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $629 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $306 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $173 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA | $58.94 |
| Regeneron Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,505 |
| Regeneron Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Travel and Lodging travel to Zurich, Switzerland | $11,019 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Consulting Fee | $5,610 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Travel and Lodging travel to Zurich, Switzerland | $552 |
| F. Hoffmann-la Roche AG Feb 3, 2025 | Travel and Lodging travel to Zurich, Switzerland | $57.85 |
| Polarean, Inc. Jan 29, 2025 | Travel and Lodging XENOVIEW · Respiratory · travel to Miami, FL · in-kind | $364 |
| Polarean, Inc. Jan 29, 2025 | Travel and Lodging XENOVIEW · Respiratory · travel to Miami, FL | $344 |
| Sanofi-aventis U.S. LLC Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,507 |
| Sanofi-aventis U.S. LLC Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,507 |
| AstraZeneca Pharmaceuticals LP Jan 13, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,028 |
| Genzyme Corporation Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $78,645 in research payments for these studies, mostly to the institutions running them.
- Ph III OLE of Astegolimab in COPD
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.